The question to open with
BPC-157 is produced in a lab. It is a peptide, or a short chain built from the parts that make up proteins.
Researchers based the lab-made chain on part of a protein they reported finding in human stomach juice.
In its September 2026 review, the FDA, the US medicine regulator, said it found no approved BPC-157 medicine in the US or other countries.
The statement about other countries reports the result of the FDA’s search of medicine records abroad.
Can we start with what this substance is, before discussing a plan?
Keep these terms apart
Peptide
The word peptide tells you how a substance is built. As of September 2026, that term alone says nothing about its safety or permission to use it as medicine.
Compounding
Compounding involves preparing a medicine for an individual patient by making or mixing it, instead of providing a product already made.
As of September 2026, compounded medicines have neither FDA approval nor an FDA check before they are marketed.
Studies in people
The FDA’s September 2026 review found few studies in people, and they watched people for only a short time.
Most reports gave too little detail to tell how researchers checked for harm.
A description tells you what something is. Evidence tells you what has been shown.
Move the visit toward your concern
Write down the problem you want assessed. Ask what may be causing it, what else could address it and how progress would be judged.
If you cannot explain a term yourself, ask the clinician for words you understand. There is no need to learn a new field just to ask for a clear answer.
Open the source drawer
These links open the documents used for this page. Ask the clinician to show you the part that supports their answer and explain anything unclear.